10% owner HRT Financial LP sold 148.3K shares (57.7% of holdings) at $0.73–$0.75 while stock down -98.3% from $394.40 high.
HRT Financial LP filed 2 separate sales totaling 148,329 shares for $110,169.41 between April 16–20, 2026, reducing holdings from 197,052 to 83,359 shares (a -57.7% net reduction). The sales occurred at $0.73 and $0.75 per share, in a company trading at $6.77 with a 52-week range of $6.77–$394.40 and a -98.3% decline from the 52-week high; Onconetix reported a -67.7% annual revenue decline, $303.7K latest-quarter revenue, and a $-8.8M net loss over the full prior fiscal year. The filing also included 1 purchase of 34,636 shares at $0.73 on April 17, interleaved between the two sales, making this a mixed transaction rather than a unidirectional liquidation. HRT's cross-ticker track record shows 7 prior sells with an average 90-day return of +307643.6% (poorly timed—stock typically rose after the sales), but same-ticker history at ONCO is nascent, with no measurable outcomes yet. The scale of this reduction, the fundamental deterioration, and the stock's catastrophic price collapse warrant investor attention to understand whether the insider view has shifted regarding Onconetix's trajectory.